MAPT and Alzheimer disease: Compared to controls, AD cases presented increased tau (p < 0.01), p-tau (p < 0.001), YKL-40 (p < 0.001), S100B (p < 0.05), and decreased Aβ42 (p < 0.001) levels (Figures 1A–E).